PURPOSE:Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers (BRCA carriers). Limited data exist for estrogen receptor (ER)-positive (+) breast cancer among BRCA carriers. INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus doxorubicin-cyclophosphamide (AC) in BRCA carriers with stage I-III human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Secondary objectives included residual cancer burden scores (RCB) of 0 or 1 (combined) and toxicity. The goal was to determine whether pCR was ≥ 20% higher with CDDP than AC. PATIENTS AND METHODS: BRCA carriers with cT1-3 (≥ 1.5 cm), cN0-3 HER2-negative breast cancer were randomly assigned to preoperative CDDP (75 mg/m2 every 3 weeks × 4 doses) or AC (doxorubicin 60 mg/m2; cyclophosphamide 600 mg/m2 every 2-3 weeks × 4 doses) followed by surgery. Pathologic responses were confirmed by central review. RESULTS:A total of 118 patients were randomly assigned; 117 were included in outcome analyses. Mean age was 42 years (range, 24-73 years); 69% were BRCA1+, 30% were BRCA2+, and 2% had both mutations. Clinical stage was I for 19%, II for 63%, and III for 18%; 45% had nodal involvement at baseline. Seventy percent had TNBC. Clinical and tumor characteristics were well matched between treatment arms. The pCR rate was 18% with CDDP and 26% with AC, yielding a risk ratio (RR) of 0.70 (90% CI, 0.39 to 1.2). The risk of RCB 0 or 1 (RCB 0/1) was 33% with CDDP and 46% with AC (RR, 0.73; 90% CI, 0.50 to 1.1). Both regimens were generally well tolerated without unexpected toxicities. CONCLUSION: pCR or RCB 0/1 is not significantly higher with CDDP than with AC in BRCA carriers with stage I-III HER2-negative breast cancer for both TNBC and ER+/HER2-negative disease.
RCT Entities:
PURPOSE:Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers (BRCA carriers). Limited data exist for estrogen receptor (ER)-positive (+) breast cancer among BRCA carriers. INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus doxorubicin-cyclophosphamide (AC) in BRCA carriers with stage I-III humanepidermal growth factor receptor 2 (HER2)-negative breast cancer. Secondary objectives included residual cancer burden scores (RCB) of 0 or 1 (combined) and toxicity. The goal was to determine whether pCR was ≥ 20% higher with CDDP than AC. PATIENTS AND METHODS: BRCA carriers with cT1-3 (≥ 1.5 cm), cN0-3 HER2-negative breast cancer were randomly assigned to preoperative CDDP (75 mg/m2 every 3 weeks × 4 doses) or AC (doxorubicin 60 mg/m2; cyclophosphamide 600 mg/m2 every 2-3 weeks × 4 doses) followed by surgery. Pathologic responses were confirmed by central review. RESULTS: A total of 118 patients were randomly assigned; 117 were included in outcome analyses. Mean age was 42 years (range, 24-73 years); 69% were BRCA1+, 30% were BRCA2+, and 2% had both mutations. Clinical stage was I for 19%, II for 63%, and III for 18%; 45% had nodal involvement at baseline. Seventy percent had TNBC. Clinical and tumor characteristics were well matched between treatment arms. The pCR rate was 18% with CDDP and 26% with AC, yielding a risk ratio (RR) of 0.70 (90% CI, 0.39 to 1.2). The risk of RCB 0 or 1 (RCB 0/1) was 33% with CDDP and 46% with AC (RR, 0.73; 90% CI, 0.50 to 1.1). Both regimens were generally well tolerated without unexpected toxicities. CONCLUSION: pCR or RCB 0/1 is not significantly higher with CDDP than with AC in BRCA carriers with stage I-III HER2-negative breast cancer for both TNBC and ER+/HER2-negative disease.
Authors: Cynthia Villarreal-Garza; Ana S Ferrigno; Alejandro Aranda-Gutierrez; Paul H Frankel; Nora H Ruel; Alan Fonseca; Steven Narod; Yanin Chavarri-Guerra; Erika Sifuentes; Maria Cristina Magallanes-Hoyos; Josef Herzog; Danielle Castillo; Rosa M Alvarez-Gomez; Alejandro Mohar-Betancourt; Jeffrey N Weitzel Journal: Cancer Res Commun Date: 2021-12-08
Authors: Yuan Yuan; Jin Sun Lee; Susan E Yost; Sierra Min Li; Paul H Frankel; Christopher Ruel; Daniel Schmolze; Kim Robinson; Aileen Tang; Norma Martinez; Daphne Stewart; James Waisman; Laura Kruper; Veronica Jones; Andrea Menicucci; Sahra Uygun; Erin Yoder; Bastiaan van der Baan; John H Yim; Christina Yeon; George Somlo; Joanne Mortimer Journal: Oncologist Date: 2020-11-08
Authors: E L Mayer; V Abramson; R Jankowitz; C Falkson; P K Marcom; T Traina; L Carey; M Rimawi; J Specht; K Miller; V Stearns; N Tung; C Perou; A L Richardson; K Componeschi; L Trippa; Z Tan-Wasielewski; K Timms; I Krop; A C Wolff; E P Winer Journal: Ann Oncol Date: 2020-08-13 Impact factor: 32.976
Authors: Allison W Kurian; Paul Abrahamse; Irina Bondarenko; Ann S Hamilton; Dennis Deapen; Scarlett L Gomez; Monica Morrow; Jonathan S Berek; Timothy P Hofer; Steven J Katz; Kevin C Ward Journal: J Natl Cancer Inst Date: 2022-02-07 Impact factor: 11.816
Authors: Foluso O Ademuyiwa; Ina Chen; Jingqin Luo; Mothaffar F Rimawi; Ian S Hagemann; Bryan Fisk; Gejae Jeffers; Zachary L Skidmore; Anamika Basu; Megan Richters; Cynthia X Ma; Katherine Weilbaecher; Jennifer Davis; Rama Suresh; Lindsay L Peterson; Ron Bose; Nusayba Bagegni; Caron E Rigden; Ashley Frith; Timothy P Rearden; Leonel F Hernandez-Aya; Anna Roshal; Katherine Clifton; Mateusz Opyrchal; Olaronke Akintola-Ogunremi; Byung Ha Lee; Sara Ferrando-Martinez; Sarah E Church; Meenakshi Anurag; Matthew J Ellis; Feng Gao; William Gillanders; Obi L Griffith; Malachi Griffith Journal: Breast Cancer Res Treat Date: 2021-06-26 Impact factor: 4.624